LETTER TO THE EDITOR
Insulin-growth-factor-1 (IGF-1): just a few steps behind the evidence in treating schizophrenia and/or autism
Rami Bou Khalil 277

EDITORIAL
FDA-approved drugs for multiple sclerosis have no efficacy or disability data in non-Caucasian patients
Jagannadha Avasarala 279

REVIEW ARTICLE
Pharmacotherapy of schizophrenia: toward a metabolomic-based approach
Haythum D. Tayeb, Hussam A. Murad, Mobahuddin M. Rateeg and Frank I. Tarazi 281

Drug–drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs
Kathie J. Goodlett, Monika T. Zmielecka and Alyssa M. Peckham 287

ORIGINAL RESEARCH
Rhythmic low-field magnetic stimulation may improve depression by increasing brain-derived neurotrophic factor
Le Xiao, Christoph U. Correll, Lei Feng, Yu Tao Xiang, Yuan Feng, Chang-Qing Hu, Rena Li and Gang Wang 313

Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine
Claudio N. Soares, Min Zhang and Matthew Bourger 322

Peripheral levels of superoxide dismutase and glutathione peroxidase in youths in ultra-high-risk for psychosis: a pilot study

Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD)
Pratap Chokka, Joanna Bougie, Emmanouil Rampakakis and Jean Proulx 338
Want some CME with that?

STAHLMASTERCLASS

• An online educational program in core areas of psychiatry with interactive readings, short lectures, animations and case studies

• Self-testing and opportunities to claim formal CME credits, all taken at a self-directed speed

• Written and moderated by experts in the field from the Dr. Stahl’s Neuroscience Education Institute and the University of Cambridge

For more information, please go to www.stahlmasterclass.com

Earn CME credits and review essential prescribing information with our apps!

NEI LEARN — for your CME needs
• Unlimited CME credits in mental health
• New activities added regularly
• Multiple learning formats
Download for FREE!

NEI PRESCRIBE — for your point-of-care needs
• 140+ psychiatric medications
• Dedicated Child and Adolescent section
• Continuously updated
• Filter to search for alternative medication options
Download for a FREE 90-day trial!

Get these apps today!
NEI website account (free) required to log in.

Visit http://nei.global to learn more!
## CONTENTS

**LETTER TO THE EDITOR**  
Insulin-growth-factor-1 (IGF-1): just a few steps behind the evidence in treating schizophrenia and/or autism  
Rami Bou Khalil  

**EDITORIAL**  
FDA-approved drugs for multiple sclerosis have no efficacy or disability data in non-Caucasian patients  
Jagannadha Avasarala  

**REVIEW ARTICLE**  
Pharmacotherapy of schizophrenia: toward a metabolomic-based approach  
Haythum O. Tayeb, Hussam A. Murad, Misbahuddin M. Rafeeq and Frank I. Tarazi  

**ORIGINAL RESEARCH**  
Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine  
Claudio N. Soares, Min Zhang and Matthieu Boucher  

Peripheral levels of superoxide dismutase and glutathione peroxidase in youths in ultra-high risk for psychosis: a pilot study  

Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD)  
Pratap Chokka, Joanna Bougie, Emmanouil Rampakakis and Jean Proulx  

Rhythmic low-field magnetic stimulation may improve depression by increasing brain-derived neurotrophic factor  
Le Xiao, Christoph U. Correll, Lei Feng, Yu-Tao Xiang, Yuan Feng, Chang-Qing Hu, Rena Li and Gang Wang  

**PERIPHERAL LEVELS OF SUPEROXIDE DISMUTASE AND GLUTATHIONE PEROXIDASE IN YOUTHS IN ULTRA-HIGH RISK FOR PSYCHOsis: A PILOT STUDY**  

Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD)  
Pratap Chokka, Joanna Bougie, Emmanouil Rampakakis and Jean Proulx  

Rhythmic low-field magnetic stimulation may improve depression by increasing brain-derived neurotrophic factor  
Le Xiao, Christoph U. Correll, Lei Feng, Yu-Tao Xiang, Yuan Feng, Chang-Qing Hu, Rena Li and Gang Wang
Editor-in-Chief
Stephen M. Stahl, Adjunct Professor of Psychiatry at the University of California San Diego, USA; Honorary Visiting Senior Fellow at the University of Cambridge, UK.

Field Editors
Jagannadha Avasarala, University of South Carolina School of Medicine, USA
Joseph F. Goldberg, Icahn School of Medicine at Mount Sinai, USA
Stefano Pallanti, University of Florence, Italy
Donatella Marazziti, University of Pisa, Italy
Thomas E. Schlaepfer, University Hospital Bonn, Germany
Frank I. Tarazi, Harvard Medical School, USA
Carlos A. Zarate, National Institute of Mental Health, USA

Deputy Editor
Thomas L. Schwartz, SUNY Upstate Medical University at Syracuse, USA

Editorial Board
Leslie Citrome, New York Medical College, USA
Christoph U. Correll, Hofstra Northwell School of Medicine, USA
Maria Conceição do Rosario, University of São Paulo Medical School, Brazil
Jeffrey L. Cummings, Cleveland Clinic, USA
Thilo Decker, Harvard Medical School, USA
Bernardo Dell’Osso, University of Milan, Italy
Koen Demyttenaere, University Psychiatric Center KuLeuven, Belgium
Karen D. Ersche, University of Cambridge, UK
Nesrin Dilbaz, Uskudar University NP Brain Hospital, Istanbul
Gianni Faedda, The Mood Disorders Center of New York, USA
Robert L. Findling, Johns Hopkins Hospital, USA
Patrick R. Finley, University of California, San Francisco, USA
Kostas N. Fountoulakis, Aristotle University of Thessaloniki, Greece
Mark S. George, Medical University of South Carolina, USA
Ira D. Glick, Stanford University, USA
Joseph F. Goldberg, Icahn School of Medicine at Mount Sinai, USA
Jon Grant, University of Chicago, USA
Gregor Hasler, University of Berne, Switzerland
Eric Hollander, Albert Einstein College of Medicine and Montefiore Medical Center, USA
Daphne Holt, Harvard Medical School, USA
Oliver Howes, King’s College, London, UK
Peter B. Jones, University of Cambridge, UK
Andres M. Kanner, University of Miami, USA
Antony D. Loebl, New York University School of Medicine, USA
Donatella Marazziti, University of Pisa, Italy
Roger McIntyre, University of Toronto, Canada
Herbert Y. Meltzer, Northwestern University, USA
Philip Mitchell, University of New South Wales, Australia
Mary Moller, Pacific Lutheran University and Northwest Integrated Health, USA
Mark Muse, Muse Psychological Associates, USA
Humberto Nicolinii, National Institutes of Health, Minister of Health, Mexico
Andrew A. Nierenberg, Harvard Medical School, USA
Stefano Pallanti, University of Florence, Italy
Katharine A. Phillips, Weill Cornell Medical College, USA
Diego A. Pizzagalli, Harvard Medical School, USA
Mark H. Pollack, Rush University Medical Center, USA
Mark H. Rapaport, Emory University, USA
Irisma Reis de Oliveira, Universidade Federal da Bahia, Brazil
Trevor W. Robbins, University of Cambridge, UK
Peter P. Roy-Byrne, University of Washington School of Medicine, USA
Barbara J. Sahakian, University of Cambridge, UK
Gerard Sanacora, Yale University School of Medicine, USA
Alan F. Schatzberg, Stanford University School of Medicine, USA
Thomas E. Schlaepfer, University of Bonn, Germany
Thomas L. Schwartz, SUNY Upstate Medical University in Syracuse, USA
Erich Seifritz, University of Zürich, Switzerland
Jordan W. Smoller, Stanford University School of Medicine, USA
Katherine D. Warburton, California Department of State Hospitals, USA
Stephen Strakowski, University of Texas at Austin, USA
T. Scott Stroup, Columbia University, USA
Frank I. Tarazi, Harvard Medical School, USA
Michael E. Thase, University of Pennsylvania, USA
Michael Trimble, National Hospital for Neurology, Queen Square, London
Madhukar H. Trivedi, University of Texas Southwestern Medical Center, USA
Hiroyuki Uchida, Keio University School of Medicine, Japan
Susan Velasquez, California Department of State Hospitals, USA
Karen Dineen Wagner, The University of Texas Medical Branch, USA
Katherine D. Warburton, California Department of State Hospitals, USA
Stephen R. Wisniewski, University of Pittsburgh, USA
Carlos A. Zarate, Jr., National Institute of Mental Health, USA
Joseph Zohar, Tel Aviv University, Israel

Managing Editor
Lisa Arrington, Cambridge University Press (larrington@cambridge.org)
Aims and Scope

**CNS Spectrums** covers all aspects of the clinical neurosciences, neurotherapeutics and neuropsychopharmacology, particularly those pertinent to the clinician and clinical investigator. The journal features focused, in-depth reviews, perspectives and original research articles. New therapeutics of all types in psychiatry, mental health, and neurology are emphasized, especially first in man studies, proof of concept studies and translational basic neuroscience studies. Subject coverage spans the full spectrum of neuropsychiatry, focusing on those crossing traditional boundaries between neurology and psychiatry.

Submitting Manuscripts to CNS Spectrums

All submissions to **CNS Spectrums** should be prepared in accordance with the instructions for authors and in the style of the Journal. Manuscripts should be submitted through the dedicated **CNS Spectrums** ScholarOne Manuscripts website: http://mc.manuscriptcentral.com/cnsspectr

CNS Spectrums will consider and encourage the following types of articles for publication: **Reviews**—The review article is a comprehensive article summarizing and synthesizing the literature on various topics presented in a scholarly and clinically relevant fashion; **Perspectives**—The perspective article is a type of review that is a short, focused summary of a single recent advance, a sort of spotlight on the topic, which could be for example, a single point hypothesis or a novel model. It can stimulate debate and new research. **Meta-guidelines**—A meta-guideline is a “guideline of guidelines” put together by several leading figures in a field in which there are multiple competing guidelines that require synthesis and updating; **Original Research**—Reports the results of a clinical study and contains original research; the journal will also include **Brainstorms** and **Editorials** that shall be commissioned or written by the Editor-in-Chief.

Instructions for Contributors

The Instructions for Contributors are available on the Cambridge Journals Online web site at: http://journals.cambridge.org/CNSifc

Indexing

**CNS Spectrums** is indexed by **Index Medicus/MEDLINE** and Web of Science (Thomson Reuters) as well as appearing in the annual Journal Citation Report. Introduced in 1996, the journal was acquired in whole by Cambridge University Press in November of 2011.

Subscriptions

Institutional print and electronic: £546/$866; Institutional electronic only: £415/$663.

© Cambridge University Press 2019. All rights reserved.

No part of this publication may be reproduced, in any form or by any means, electronic, photocopying, or otherwise, without permission in writing from Cambridge University Press. Policies, request forms, and contacts are available at: http://www.cambridge.org/rights/permissions/permission.htm. Permission to copy (for users in the U.S.A.) is available from Copyright Clearance Center http://www.copyright.com, email: info@copyright.com.

Rights & permissions requests can be applied for online within each article by clicking “Request Permissions” within the table of contents or in the fulltext version of a specific article. Requests will be processed via the CCC Rightslink system and processed immediately.

**CNS Spectrums** (ISSN: Print 1092-8529; eISSN: 2165-6509) is published bimonthly by Cambridge University Press.

Postmaster


Online availability

**CNS Spectrums** is hosted on the Cambridge Core service at cambridge.org/cns

Institutional subscribers: Access to full-text articles online is only granted to subscription options offering an online component. Subscriptions must be activated by the purchasing institution using the instructions provided at the time of purchase; see information for subscribers at: http://journals.cambridge.org/

Reprint and Advertising Sales

Inquiries for bulk reprint sales should be sent to USReprints@cambridge.org. Advertising inquiries should be sent to M. J. Mrvica Associates, Inc., 2 West Taunton Avenue, Berlin, NJ 08009; Phone: 856-768-9360; Fax: 856-753-0084; Email: mjmrvica@mrvica.com.

https://doi.org/10.1017/S1092852919001123 Published online by Cambridge University Press